The primary reason of this study is to observe current and past treatment in adult participants receiving Vedolizumab, intravenous (IV) or subcutaneous (SC), for IBD in Brazil. There is no treatment involved in this study, this is only an observational review of past and ongoing treatment data relating to Vedolizumab treatment for IBD (including Ulcerative Colitis \[UC\] and Crohn's Disease \[CD\]).
This is a non-interventional, observational study in participants with IBD participating in the PSP. This study will enroll approximately 2160 participants. The study is divided into two cohorts according to data collection: * Retrospective Cohort * Prospective Cohort The retrospective cohort is for participants that were included in the PSP prior to study start. This retrospective cohort will have data of participants that are actively participating in the Program and only their retrospective data will be collected. The prospective cohort is for participants that are starting their participation in the PSP using their data from the consent date until the end of the study or until the discontinuation in the PSP or in the study. Retrospective and prospective cohorts will be collected from the PSP database, which will be the only source of participants for this study. This single country trial will be conducted in Brazil. The duration of this observational study will be approximately 26 months.
Study Type
OBSERVATIONAL
Enrollment
1,006
This is a non-interventional study.
Pesquisare Saúde S/S Ltda
Santo André, São Paulo, Brazil
Number of Participants With Vedolizumab Treatment Persistence for Conventional Therapy and Advanced Therapies
Treatment persistence will be defined as participants who did not discontinue treatment during follow-up. Advance therapies include biologics and tofacitinib.
Time frame: Up to approximately 9 years
Number of Participants With Therapies Used Before Vedolizumab Treatment
Time frame: Up to approximately 9 years
Number of Participants With Vedolizumab Treatment Scheme (Dose Escalation and De-escalation) for Conventional and Advanced Therapies
Advance therapies include biologics and tofacitinib.
Time frame: Up to approximately 9 years
Number of Participants With Comorbidities Associated or not With CD or UC
Time frame: Up to approximately 9 years
Duration of Disease
Time frame: Up to approximately 9 years
Percentage of Participants Diagnosed With UC or CD
Time frame: Up to approximately 9 years
Percentage of Participants With Vedolizumab Drug Administration Route: Intravenous (IV) or Subcutaneous (SC)
Time frame: Up to approximately 9 years
Number of Participants Based on Quality-of-life (QOL) as Assessed by Short Inflammatory Bowel Disease Questionnaire 10 (SIBDQ-10) in Prospective Cohort
The SIBDQ is a validated tool used by health care professionals for assessment of participant's inflammatory bowel disease. SIBDQ contains 10 (ten) questions, and each question is composed of the 7 (seven) levels of self-perception of feeling or mood, giving an absolute score ranging from 10 (poor health related QoL) to 70 (optimal health related QoL), higher scores mean better quality of life. Index date will be defined as the start of the vedolizumab treatment.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: At the index date (vedolizumab initiation), and at 14 and 52 weeks from index date
Percentage of Participants With Adverse Events (AEs) or Serious AEs During Vedolizumab use for UC and CD
Time frame: Up to approximately 9 years
Number of Participants With Reason for Discontinuing the Vedolizumab Treatment for Conventional Therapy and Experiences Anti-TNF
Time frame: Up to approximately 9 years